temozolomide

[Cell Death & Disease] Researchers reported on the novel mechanism whereby overexpressed class I histone deacetylases increase the resistance of glioblastoma cells to the SN1 methylating agent temozolomide.

[Laboratory Investigation] Scientists treated glioblastoma cells with RSL3, a ferroptosis inducer, in vitro cell lines and in vivo subcutaneous and orthotopic animal models.

[Cell Death & Differentiation] Depletion of glycosyltransferase 8 domain containing 1 (GLT8D1) inhibited self-renewal of glioma stem cells in vitro and repressed tumor growth in glioma mouse models.

[Scientific Reports] Nine compounds demonstrated desirable glioblastoma cell toxicity in cell culture, and two of them, HR51, and HR59 demonstrated significantly improved capability of crossing the model blood–brain-barrier composed of endothelial cells, astrocytes and pericytes.

[Journal of Experimental & Clinical Cancer Research] The authors demonstrated that enhanced secretory autophagy in glioblastoma (GB) facilitated M1-like polarization of tumor associated macrophages to enhance temozolomide sensitivity of GB cells.

[Cancer Research] Investigators showed that LAMP2A expression was enriched in patient-derived glioblastoma stem cells (GSC), and its depletion diminished GSC-mediated tumorigenic activities.